1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Sino Medical Sciences Technology Inc. Class A

Sino Medical Sciences Technology Inc. Class A

SSSE:688108
13.28
CNY
-0.46
(-3.35%)
7.74BMarket Cap
Oct 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.3
1.41
1.07
1.16
0.73
0.48
0.48
0.87
1.23
1.22
- -
Basic EPS, GAAP
0.14
0.29
0.25
0.24
0.05
-0.32
-0.4
-0.1
- -
0.11
- -
Free Cash Flow per Basic Share
-0.01
-0.03
- -
-0.11
-0.09
-0.53
-0.55
-0.03
0.16
0.27
- -
Dividend per Share
0.08
0.04
- -
- -
0.09
- -
- -
0.01
0.01
0.01
0.01
Book Value per Share
0.56
1.69
1.95
2.68
2.63
2.26
2.07
2
2.1
2.23
2.39
Tangible Book Value per Share
0.35
1.37
1.47
2.03
1.87
1.48
1.2
1.06
0.58
0.71
0.91
Basic Weighted Avg Shares
205
228
357
375
450
409
406
396
374
430
414
Sales/Revenue/Turnover
266
322
380
436
327
194
193
343
459
525
- -
Operating Margin (%)
15.04
25.36
26.94
23.61
4.17
-80.3
-103.71
-16.84
-1.57
14.31
- -
Depreciation Expense
16
18
21
28
38
65
63
63
78
75
- -
Net Income, GAAP
29
66
89
90
22
-131
-162
-40
1
47
- -
Effective Tax Rate (%)
29.01
17.87
13.15
16.61
22.01
- -
- -
- -
- -
30.65
- -
Profit Margin (%)
10.79
20.54
23.45
20.65
6.87
-67.28
-84.2
-11.55
0.33
9
- -
Working Capital
87
422
452
728
621
338
223
193
211
187
356
LT Debt
- -
- -
- -
- -
40
27
12
75
74
15
34
Total Equity
203
607
701
1,099
1,078
945
887
862
898
960
1,072
Return on Invested Capital (%)
- -
16.32
14.2
9.99
1.68
- -
- -
- -
- -
4.16
- -
Return on Capital (%)
- -
16.21
13.4
9.55
1.61
- -
- -
- -
- -
4.57
- -
Return on Common Equity (%)
- -
16.34
13.64
10.01
2.07
-13.04
-18.3
-4.75
0.18
5.27
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
197
118
117
LT Borrowings
- -
9
23
LT Finance Leases
15
13
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
416
418
418
Market Capitalization
8,005
8,501
7,745

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
520
514
571
Cash, Cash Equivalents & STI
396
376
430
Accounts Receivable, Net
25
28
25
Inventories
89
93
87
Total Current Liabilities
334
202
214
Payables & Accruals
- -
- -
- -
ST Debt
197
118
117
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.04%
6.84%
Free Cash Flow
- -
-50.43%
89.59%
Net Income, GAAP
- -
444.1%
3,057.07%
Sales/Revenue/Turnover
- -
16.95%
14.53%
Total Cash Common Dividend
- -
642.61%
2.06%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
123
105
140
459
2025
101
140
- -
162
525
2026
140
165
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.01
-0.03
0.03
- -
2025
0.01
0.03
- -
0.06
0.11
2026
0.06
0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Hua Sun
Full Time Employees
649
Sector
Health technology
Industry
Medical specialties
Address
TEDA Biopharm Res, Building B Tianjin TI China 300457
IPO Date
Oct 30, 2019
Website
sinomed.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sino Medical Sciences Technology Inc. (SINOMED) engages in the research, development, production and sales of high-end interventional medical devices for cardiovascular, cerebrovascular and structural heart diseases. The company offers a comprehensive portfolio of products across coronary intervention, neurointervention and structural heart disease segments; coronary intervention products include drug-eluting stents such as BuMA Supreme, HT Supreme healing-targeted drug coated stent system, BuMA biodegradable-drug-coating stent system and biodegradable magnesium drug-eluting stent system, coronary balloon catheters such as Tradent coronary scoring balloon catheter, SC Honkytonk PTCA balloon dilatation catheter, NC Rockstar non-compliant PTCA balloon dilatation catheter, Tytrak semi-compliant coronary balloon catheter and NC Thonic non-compliant coronary balloon catheter, and vascular access products such as Mariyana coronary guide extension catheter; neurointervention products encompass intracranial stenosis solutions like NOVA DES intracranial drug-eluting stent system, Neuro LPS intracranial balloon dilation catheter and COMETIU intracranial self-expanding drug stent system, ischemic stroke devices including COVESTAR balloon guide catheter, GHUNTER revascularization device, APACHI intracranial thrombosis aspiration catheter, TORR aspiration system and LEATUBE aspiration tubing, intracranial aneurysm treatments such as AUCURA coated flow diverter, and access delivery systems like OPTIMUS delivery catheter, APEX TRA radial access catheter system, Rayline micro catheter and NOVARAIL distal access catheter; structural heart disease offerings feature the AccuFit transapical mitral valve replacement (TMVR) system. Founded on September 21, 2007 and headquartered in Tianjin, China, SINOMED operates primarily in the domestic Chinese market with products used in over 2,000 hospitals and expanding global access through more than 200 patents in China, the United States and Europe. In a recent strategic move, the company agreed to acquire a 72.7% stake in eLum Technologies LLC from Decheng Capital to bolster its interventional device capabilities.